Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of GSK3923868 in Healthy Participants of Diverse Ancestry
NCT06577597Phase 1Completed
- Sponsor
- GSK
- Start
- Sep 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory tract infection (RTI) and human rhinovirus infection comparing GSK3923868 with Placebo (2 arms). Primary endpoints: Number of Participants with Adverse events, Number of Participants with Serious Adverse events and 9 more. Started Sep 2024; status: completed.
02
Drugs
GSK3923868
03
Conditions
respiratory tract infection (RTI)human rhinovirus infection
Beyond the preview
Go deeper on NCT06577597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577597.